Literature DB >> 16045826

TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?

Sonja Merkesdal1, Henning Zeidler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16045826     DOI： 10.1007/s11926-005-0032-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  18 in total

Review 1.  OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis.

Authors:  Sherine Gabriel; Michael Drummond; Andreas Maetzel; Maarten Boers; Doug Coyle; Vivian Welch; Peter Tugwell
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

2.  Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

Authors:  J Ledingham; C Deighton
Journal:  Rheumatology (Oxford)       Date:  2005-01-05       Impact factor: 7.580

3.  Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.

Authors:  Paco M J Welsing; Johan L Severens; Margriet Hartman; Piet L C M van Riel; Roland F J M Laan
Journal:  Arthritis Rheum       Date:  2004-12-15

4.  Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.

Authors:  G Kobelt; P Lindgren; A Singh; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

Review 5.  Cost-effectiveness of anti-tumor necrosis factor agents.

Authors:  J B Wong
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

6.  Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

Authors:  N J Bansback; A Brennan; O Ghatnekar
Journal:  Ann Rheum Dis       Date:  2004-11-18       Impact factor: 19.103

7.  The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.

Authors:  S J Bingham; M H Buch; A Tennant; P Emery
Journal:  Rheumatology (Oxford)       Date:  2003-12-01       Impact factor: 7.580

8.  TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.

Authors:  G Kobelt; K Eberhardt; P Geborek
Journal:  Ann Rheum Dis       Date:  2004-01       Impact factor: 19.103

Review 9.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

10.  A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.

Authors:  Hyon K Choi; John D Seeger; Karen M Kuntz
Journal:  J Rheumatol       Date:  2002-06       Impact factor: 4.666
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.